Logo image of SCNI

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SCNI - US09073Q3039 - ADR

0.9359 USD
+0.01 (+1.34%)
Last: 11/26/2025, 8:02:58 PM
Fundamental Rating

1

SCNI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of SCNI have multiple concerns. SCNI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SCNI was profitable.
SCNI had a negative operating cash flow in the past year.
SCNI had negative earnings in 4 of the past 5 years.
SCNI had a negative operating cash flow in each of the past 5 years.
SCNI Yearly Net Income VS EBIT VS OCF VS FCFSCNI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of SCNI (40.51%) is better than 99.06% of its industry peers.
The Return On Equity of SCNI (61.03%) is better than 98.87% of its industry peers.
Industry RankSector Rank
ROA 40.51%
ROE 61.03%
ROIC N/A
ROA(3y)-7.65%
ROA(5y)-13.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCNI Yearly ROA, ROE, ROICSCNI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

1.3 Margins

SCNI has a Profit Margin of 728.88%. This is amongst the best in the industry. SCNI outperforms 99.25% of its industry peers.
The Operating Margin and Gross Margin are not available for SCNI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 728.88%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCNI Yearly Profit, Operating, Gross MarginsSCNI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

More info and screens

1

2. Health

2.1 Basic Checks

SCNI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCNI has more shares outstanding
SCNI has more shares outstanding than it did 5 years ago.
SCNI has a better debt/assets ratio than last year.
SCNI Yearly Shares OutstandingSCNI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SCNI Yearly Total Debt VS Total AssetsSCNI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

SCNI has an Altman-Z score of -16.36. This is a bad value and indicates that SCNI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.36, SCNI is doing worse than 81.80% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that SCNI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.04, SCNI perfoms like the industry average, outperforming 41.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -16.36
ROIC/WACCN/A
WACC6.64%
SCNI Yearly LT Debt VS Equity VS FCFSCNI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

SCNI has a Current Ratio of 0.71. This is a bad value and indicates that SCNI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of SCNI (0.71) is worse than 89.87% of its industry peers.
A Quick Ratio of 0.71 indicates that SCNI may have some problems paying its short term obligations.
The Quick ratio of SCNI (0.71) is worse than 89.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.71
SCNI Yearly Current Assets VS Current LiabilitesSCNI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%172.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNI Yearly Revenue VS EstimatesSCNI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 200K 400K 600K
SCNI Yearly EPS VS EstimatesSCNI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 -20 -40 -60

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SCNI is valuated cheaply with a Price/Earnings ratio of 0.31.
Compared to the rest of the industry, the Price/Earnings ratio of SCNI indicates a rather cheap valuation: SCNI is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SCNI to the average of the S&P500 Index (26.15), we can say SCNI is valued rather cheaply.
Industry RankSector Rank
PE 0.31
Fwd PE N/A
SCNI Price Earnings VS Forward Price EarningsSCNI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNI Per share dataSCNI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SCNI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCINAI IMMUNOTHERAPEUTICS LT

NASDAQ:SCNI (11/26/2025, 8:02:58 PM)

0.9359

+0.01 (+1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2024-05-15/amc
Earnings (Next)N/A N/A
Inst Owners7.84%
Inst Owner Change28.57%
Ins Owners2.37%
Ins Owner ChangeN/A
Market Cap2.95M
Revenue(TTM)658.00K
Net Income(TTM)4.80M
Analysts82.86
Price TargetN/A
Short Float %1.91%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.31
Fwd PE N/A
P/S 4.48
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)3.03
EY323.75%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.21
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number13.04
Profitability
Industry RankSector Rank
ROA 40.51%
ROE 61.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 728.88%
GM N/A
FCFM N/A
ROA(3y)-7.65%
ROA(5y)-13.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.94%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.71
Altman-Z -16.36
F-Score5
WACC6.64%
ROIC/WACCN/A
Cap/Depr(3y)91.14%
Cap/Depr(5y)108.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%172.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.48%
OCF growth 3YN/A
OCF growth 5YN/A

SCINAI IMMUNOTHERAPEUTICS LT / SCNI FAQ

What is the fundamental rating for SCNI stock?

ChartMill assigns a fundamental rating of 1 / 10 to SCNI.


What is the valuation status for SCNI stock?

ChartMill assigns a valuation rating of 2 / 10 to SCINAI IMMUNOTHERAPEUTICS LT (SCNI). This can be considered as Overvalued.


Can you provide the profitability details for SCINAI IMMUNOTHERAPEUTICS LT?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for SCNI stock?

The Price/Earnings (PE) ratio for SCINAI IMMUNOTHERAPEUTICS LT (SCNI) is 0.31 and the Price/Book (PB) ratio is 0.38.